Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry

被引:14
作者
Corzo, C
Tusquets, I
Salido, M
Corominas, JM
Bellet, M
Suarez, M
Baró, T
Fabregat, X
Serrano, S
Solé, F
机构
[1] Hosp del Mar, IMAS, Unitat Rec Translac Tumors Solids,Serv Patol, Lab Citogenet & Biol Mol, ES-08003 Barcelona, Spain
[2] Hosp del Mar, IMAS, Unitat Rec Translac Tumors Solids, Med Oncol Serv, ES-08003 Barcelona, Spain
[3] Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, E-08193 Barcelona, Spain
关键词
epidermal growth factor receptor; fluorescence in situ hybridization; HER1; immunohistochemistry; locally advanced breast cancer;
D O I
10.1159/000084183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidermal growth factor receptor ( EGFR) is a 170-kDa transmembrane glycoprotein encoded by the HER1 protooncogene, located at 7p12. This receptor is related to the pathogenesis of breast cancer. The aim of this study was to analyze the status of HER1 using fluorescence in situ hybridization ( FISH) and immunohistochemistry in a series of 48 patients with locally advanced breast cancer (LABC). Before neoadjuvant chemotherapy, core biopsies were taken from patients with LABC and were processed into paraffin blocks. Biopsies were then studied using FISH with a HER1 probe (Vysis, Downers Grove, Ill., USA). They were also analyzed immunohistochemically using two different EGFR antibodies from DakoCytomation ( Denmark, A/S) and from Zymed ( San Francisco, Calif., USA). HER1 amplifications were not found, although 31% of the cases presented aneusomy of chromosome 7. Only 2 cases presented EGFR expression. LABC presented a low level of EGFR expression. HER1 amplification was not present in LABC, although the polysomy of chromosome 7 was a common finding. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 30 条
[1]  
Arteaga CL, 2001, J CLIN ONCOL, V19, p32S
[2]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[3]   Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing [J].
Baselga, J .
ANNALS OF ONCOLOGY, 2002, 13 (01) :8-9
[4]  
Baselga J, 2001, J CLIN ONCOL, V19, p41S
[5]  
Brabender J, 2001, CLIN CANCER RES, V7, P1850
[6]  
Chen Z, 2000, ANTICANCER RES, V20, P899
[7]  
Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
[8]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[9]   THE EPIDERMAL GROWTH-FACTOR RECEPTOR AS A PROGNOSTIC MARKER - RESULTS OF 370 PATIENTS AND REVIEW OF 3009 PATIENTS [J].
FOX, SB ;
SMITH, K ;
HOLLYER, J ;
GREENALL, M ;
HASTRICH, D ;
HARRIS, AL .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 29 (01) :41-49
[10]   Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer [J].
Järvinen, TAH ;
Tanner, M ;
Rantanen, V ;
Bärlund, M ;
Borg, Å ;
Grénman, S ;
Isola, J .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03) :839-847